Syndax Pharmaceuticals Inc
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M |
| Operating expenses | $445.4M | $363.4M | $230.0M | $151.8M | $113.5M |
| Cash from operations | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M |
| Capital expenditure | $187,000 | $0 | $0 | $0 | $129,000 |
| Free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | $29.0M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M |
| Total debt | — | — | — | — | $20.0M |
Shares outstanding 88.6M · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.